Prediction of response to revascularization in patients with renal artery stenosis by Tc-99m-ethylenedicysteine captopril scintigraphy

Annals of Nuclear Medicine

Volumn 13, Issue 2, 1999, Pages 77-81

  Uǧur, Ömer ^a   Serdengeçti, Mustafa ^b   Karacalioǧlu, Özgür ^b   Ergün, Eser Lay ^a   Peksoy, Irfan ^a   Çekirge, Saruhan ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Captopril scintigraphy; Renal artery stenosis; Renovascular hypertension; Tc 99m ethylenedicysteine

Indexed keywords

CAPTOPRIL; CYSTEINE ETHYL ESTER TC 99M;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; FEMALE; HUMAN; IMAGE ANALYSIS; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; KIDNEY SCINTISCANNING; MALE; NEPHROSCLEROSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; RESTENOSIS; REVASCULARIZATION;

EID: 18844467698     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03164881     Document Type: Article

References (14)

1. Kabasakal L, Turoglu HT, Onsel C, et al. Clinical comparison of technetium-99m-EC, technetium-99m-MAG3 and iodine-131-OIH in renal disorders. J Nucl Med 36: 224-228, 1995.
2. Uǧur Ö, Caner B, Cekirge S, et al. The diagnosis of renovascular hypertension with technetium-99m-ethylenedicysteine captopril scintigraphy. Invest Radiol 31: 497-501, 1996.
3. 99mTc-EC captopril test in patients with hypertension. Nucl Med Commun 16: 128-131, 1995.
4. Detection, evaluation and treatment of renovascular hypertension. Final Report Working group on renovascular hypertension. Arch Intern Med 147: 820-829, 1987.
5. Harrison Jr EG, McCormack LJ. Pathologic classification of renal arterial disease in renovascular hypertension. Mayo Clin Proc 46: 161-167, 1971.
6. Maxwell MH, Bleifer KH, Franklin SS, Varady PH. Cooperative study of renovascular hypertension. Demographic analysis of the study. JAMA 220: 1195-1204, 1972.
7. Taylor A, Nally J, Aurell M, et al. Consensus report on ACE inhibitor renography for detecting renovascular hypertension. J Nucl Med 37: 1876-1882, 1996.
8. Blaufox MD, Middleton ML, Bongiovanni J, Davis BR. Cost efficacy of the diagnosis and therapy of renovascular hypertension. J Nucl Med 37: 171-177, 1996.
9. Blaufox MD, Dubovsky EV, Hilson AJW, et al. Report of the working party group on determining the radionuclide of choice. Am J Hypertens 4: 747S-748S, 1991.
10. Dondi M, Fanti S, De Fabritiis A, et al. Prognostic value of captopril renal scintigraphy in renovascular hypertension. J Nucl Med 33: 2040-2044, 1992.
11. Meier GH, Sumpio B, Setaro JF. Captopril renal scintigraphy: a new standard for predicting outcome after renal revascularization. J Vasc Surg 17: 280-287, 1993.
12. Kibar M, Tutuş A, Paydas S, Reyhan M. Captopril-enhanced Tc-99m-N,N-ethylene dicysteine renal scintigraphy in patients with suspected renovascular hypertension: a comparative study with Tc-99m-MAG3. Eur J Nucl Med 24: 1001, 1997. (abstract)
13. Uǧur Ö, Peksoy I, Caner B. Technetium-99m-ethylenedicysteine: An alternative agent to detect renovascular hypertension. J Nucl Med 38: 1662-1664, 1997.
14. Uǧur Ö, Serdengeçti M, Karacalioǧlu Ö, et al. Comparison of EC and DTPA captopril scintigraphies for the detection of renal artery stenosis and the prediction of outcome after revascularization. J Nucl Med 39: 199P, 1998. (abstract)